This reports provides a data-driven overview of the current and future competitive landscape in BDD therapeutics.
- There will be 67,698,071 total prevalent cases of BDD in 2023 in the 16 countries covered in the publisher's epidemiology forecast
- No approved marketed drugs are currently available for the treatment of BDD
- R&D activity within the BDD space is negligible, with no pipeline products in late-stage clinical development
- Non-commercial sponsors currently dominate the BDD clinical development space
- No deals were implemented among companies developing BDD assets in the past 24 months
Scope
The publisher's Body Dysmorphic Disorder (BDD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Pricing and Reimbursement Assessment
- Pipeline Assessment
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the BDD market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BDD market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Preface
3 Disease Landscape
4 Marketed Drugs Assessment
6 Pipeline Drugs Assessment
7 Clinical Trials Assessment
9 Commercial Assessment
11 Appendix
